Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.
Vigil Neuroscience has reported early clinical data on its Alzheimer’s disease candidate, positioning the biotech to advance its small molecule in the footsteps of AbbVie and Alector’s failed rival ...
LAUREL COUNTY, Ky. (WYMT) - It has been one month since one Laurel County man was shot to death in his home by London Police. Community members are set to honor the life of Doug Harless at 6:30 pm. on ...